Jefferies Assumes Inozyme Pharma at Buy, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Maury Raycroft assumes Inozyme Pharma (NASDAQ:INZY) with a Buy rating and raises the price target to $17.
August 13, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Maury Raycroft has assumed coverage of Inozyme Pharma with a Buy rating and increased the price target to $17.
The Buy rating and increased price target from a reputable analyst at Jefferies is likely to boost investor confidence in Inozyme Pharma, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100